Novo Nordisk v. Mylan: Semaglutide Patent Suit Dismissed in 34 Days
Novo Nordisk filed suit against Mylan in the West Virginia Northern District Court asserting two patents covering its Ozempic semaglutide injection formulations against Mylan’s proposed 2 mg/3 mL generic. The action was voluntarily dismissed without prejudice under Rule 41 just 34 days after filing — before any substantive merits ruling.
A lightning-fast ANDA patent exit: Novo Nordisk steps back from Mylan semaglutide suit
On 2 July 2024, Novo Nordisk A/S filed a patent infringement action against Mylan NV in the US District Court for the Northern District of West Virginia, asserting two patents — US8129343B2 and US10335462B2 — covering semaglutide injection formulations. The suit was framed as an infringement action in the context of Mylan’s proposed generic semaglutide injection product (2 mg/3 mL, 0.68 mg/mL), challenging Mylan’s right to commercialise a product referencing Novo Nordisk’s blockbuster Ozempic franchise.
Just 34 days after filing, on 5 August 2024, Novo Nordisk invoked Federal Rule of Civil Procedure 41(a)(1)(A)(i) to file a voluntary notice of dismissal without prejudice. Judge Thomas S. Kleeh entered the order striking the case from the active docket. Because no answer or motion for summary judgment had been served by Mylan, Novo Nordisk was entitled to dismiss as of right — no court permission was required. The without-prejudice designation means Novo Nordisk retains the legal option to reassert the same claims in a future action.
The 34-day lifespan is exceptionally short even by ANDA litigation standards, where cases routinely run for years before trial. The public record offers no explanation for the rapid exit — possible drivers include parallel settlement negotiations, a licensing arrangement, a strategic decision to refile in a different venue, or a reassessment of claim strength. No Defendant agents or law firms are recorded, suggesting Mylan may not have formally appeared before the dismissal was filed. What drove Novo Nordisk’s decision remains unknown from the public docket.
Filing to Voluntary dismissal in 34 days
34 days — well below the median ANDA patent litigation duration of 2–3 years
Voluntarily dismissed without prejudice: what the order means for both sides
Rule 41(a)(1)(A)(i): dismissal as of right, no court permission needed
Under FRCP Rule 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order by filing a notice before the opposing party serves an answer or motion for summary judgment. Because no Defendant agents are recorded here, Mylan appears not to have formally appeared, meaning Novo Nordisk could exit unilaterally. The court’s role was ministerial — it simply ordered the case stricken from the docket.
Procedural exit, no merits rulingNovo Nordisk preserves its right to refile — the clock has not run out
A without-prejudice dismissal leaves the legal landscape largely unchanged: Novo Nordisk’s patents remain enforceable, the claims were never adjudicated, and the company may bring a new action asserting the same patents against Mylan’s semaglutide product in the future. This contrasts sharply with a with-prejudice dismissal, which would bar refiling. The public record here is explicit — the order states ‘DISMISSED WITHOUT PREJUDICE’ — so there is no ambiguity about which form of dismissal applies.
Refiling right preservedMylan faces no injunction — but the patent threat has not been extinguished
Mylan obtains a clear docket for now: no judgment, no injunction, and no damages award has been entered against it. However, because the dismissal was without prejudice, Mylan cannot treat this as a victory on the merits. The two asserted patents — US8129343B2 and US10335462B2 — remain live and could be reasserted. Mylan would be prudent to continue monitoring Novo Nordisk’s enforcement posture before advancing its generic semaglutide launch timeline.
No merits clearance for MylanGeneric semaglutide entry remains legally uncertain after this dismissal
The dismissal does not signal a patent-free path for Mylan’s generic semaglutide injection. Novo Nordisk holds a broad portfolio around the Ozempic franchise, and the two patents here cover formulation-level protections that could be re-litigated. For the broader generics sector, this case is a reminder that early dismissals in ANDA-style litigation often precede settlement negotiations or parallel proceedings rather than signalling an innovator’s retreat from enforcement.
Generic entry still patent-encumberedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novo Nordisk A/S | Individual | Global pharmaceutical innovator — holder of US8129343B2 and US10335462B2 covering semaglutide formulationsSearch in Eureka ↗ |
| Co-Plaintiff | Novo Nordisk A/S | Individual | Search in Eureka ↗ |
| Defendant | Mylan, NV | Company | Mylan NV — global generic pharmaceutical manufacturer seeking to market biosimilar/generic semaglutide injectionSearch in Eureka ↗ |
| Plaintiff counsel | Erica R. Sutter | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | James F. Companion | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Jeffrey J. Oelke | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Laura T. Moran | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Olivia L. Wheeling | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Robert E. Counihan | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Ryan P. Johnson | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Sandra K. Law | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Vanessa Park Thompson | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff law firm | Fenwick & West LLP | Law Firm | Representing Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff law firm | Schrader Companion Duff & Law, PLLC | Law Firm | Representing Novo Nordisk A/SSearch in Eureka ↗ |
| Presiding judge | Judge Thomas S Kleeh | Judge | West Virginia Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The order adopts the precise language of Rule 41(a)(1)(A)(i), confirming this was a plaintiff-initiated dismissal as of right rather than a court-ordered or negotiated disposition. The explicit ‘WITHOUT PREJUDICE’ designation is legally significant: it preserves Novo Nordisk’s full right to refile the same claims against Mylan’s semaglutide product. No merits analysis, claim construction, or damages finding accompanies the order — the patents’ validity and infringement remain entirely unadjudicated.
US8129343B2 & US10335462B2 — semaglutide injection formulation patents
US8129343B2 (application no. US11/908834) and US10335462B2 (application no. US15/656042) both relate to semaglutide — a GLP-1 receptor agonist peptide used in subcutaneous injection formulations for type 2 diabetes and obesity management. These patents cover formulation-level protections for the active pharmaceutical ingredient and its delivery system, directly underpinning Novo Nordisk’s Ozempic product line across multiple concentration presentations (0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL).
Semaglutide has become one of the most commercially significant pharmaceutical compounds globally, driving intense generic and biosimilar entry interest. Formulation patents like US8129343B2 and US10335462B2 are strategically critical because they extend protection beyond the compound patent itself, creating layered enforcement options. Any generic or biosimilar sponsor referencing Ozempic in an ANDA or 505(b)(2) filing must navigate these patents, making FTO clearance against the full Novo Nordisk semaglutide portfolio essential before any launch decision.
Should you run an FTO against US8129343B2 and US10335462B2?
Any pharmaceutical company, contract manufacturer, or formulation developer working on GLP-1 receptor agonist injectables — particularly semaglutide-based products — should treat US8129343B2 and US10335462B2 as mandatory FTO targets. This case confirms Novo Nordisk is willing to assert both patents aggressively against generic entrants. Even a without-prejudice dismissal does not clear these patents from the enforcement landscape; the threat can be reasserted at any time against the same or similar products.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map the full Novo Nordisk semaglutide patent portfolio, identify claim scope overlaps with proposed formulations, track prosecution history for potential design-around opportunities, and monitor for new continuations or divisionals. Given the commercial stakes of the Ozempic franchise, running a structured FTO before committing to a generic semaglutide development programme is not optional — it is a commercial necessity.
Run a freedom-to-operate analysis on US8129343B2 to assess your product’s exposure
Run FTO in Eureka →Similar semaglutide and GLP-1 patent infringement cases in US district courts
Explore comparable pharmaceutical patent infringement actions involving semaglutide and GLP-1 formulation patents filed in US district courts, including ANDA-related Novo Nordisk enforcement matters.
What this case signals for the semaglutide and GLP-1 patent landscape
A 34-day voluntary dismissal in an ANDA-adjacent semaglutide suit rarely signals a clean exit — it typically signals strategy in motion.
Early voluntary dismissals in pharma patent suits are often tactical, not terminal
When an innovator dismisses without prejudice before the defendant has even appeared, it typically suggests a parallel track — settlement, licensing, or a venue change — rather than an abandonment of rights. Novo Nordisk’s swift exit here is consistent with that pattern. Patent professionals monitoring Ozempic generic entry should watch for refiled actions or PTAB proceedings against the same Mylan product.
US8129343B2 and US10335462B2 remain live enforcement assets for Novo Nordisk
Neither patent was invalidated, licensed away, or adjudicated in this action. Both formulation patents covering the semaglutide injection franchise remain in force. Companies developing or distributing GLP-1 receptor agonist injectables — including biosimilar and generic entrants — should treat these patents as active blocking risks and conduct updated FTO analysis before any commercial launch.
A/S v Mylan — key questions answered
Novo Nordisk voluntarily dismissed its patent infringement action against Mylan without prejudice on 5 August 2024, just 34 days after filing. The suit asserted US8129343B2 and US10335462B2 against Mylan’s proposed semaglutide injection product. No merits ruling was issued.
Novo Nordisk asserted two patents: US8129343B2 (application US11/908834) and US10335462B2 (application US15/656042). Both cover semaglutide injection formulations underlying the Ozempic product line. Neither patent was adjudicated — the case ended before any substantive merits hearing.
A without-prejudice dismissal means Novo Nordisk’s patents were not invalidated or held not infringed. The company retains the full legal right to refile the same claims against Mylan’s semaglutide product in a future action. The patents US8129343B2 and US10335462B2 remain in force and enforceable.
The dismissal without prejudice does not provide Mylan with patent clearance. No court found the asserted patents invalid or not infringed. Novo Nordisk could refile, and Mylan would need to navigate the full Novo Nordisk semaglutide patent portfolio — including US8129343B2 and US10335462B2 — before any commercial launch.
The public record does not disclose the reason. The 34-day timeline and the fact that Mylan appears not to have formally appeared are consistent with several scenarios: pre-litigation settlement or licensing discussions, a strategic decision to refile in a different venue, or a reassessment of enforcement timing. No explanation is given in the court order.
PatSnap Eureka searches patents and litigation data to answer instantly.